Kura Oncology (NASDAQ:KURA) Stock Price Up 9.6% – What’s Next?

Posted by Brenda Bartman on Oct 22nd, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report)’s share price shot up 9.6% during trading on Tuesday. The company traded as high as $10.11 and last traded at $10.26. 325,621 shares traded hands during trading, a decline of 81% from the average session volume of 1,670,903 shares. The stock had previously closed at $9.36.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on KURA shares. Barclays set a $24.00 target price on Kura Oncology in a research report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft set a $24.00 price target on Kura Oncology in a research report on Wednesday, October 14th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Finally, Morgan Stanley set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.35.

View Our Latest Analysis on KURA

Kura Oncology Stock Performance

The stock has a fifty day simple moving average of $11.38 and a two-hundred day simple moving average of $10.37. The stock has a market cap of $878.92 million, a price-to-earnings ratio of -2.93 and a beta of 0.47. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Analysts expect that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Insider Activity

In other news, insider Brian Powl sold 17,020 shares of the stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.53, for a total value of $179,220.60. Following the completion of the transaction, the insider owned 152,249 shares of the company’s stock, valued at approximately $1,603,181.97. This represents a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Teresa Bair sold 31,487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the completion of the sale, the insider owned 195,444 shares in the company, valued at approximately $2,468,457.72. The trade was a 13.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 153,881 shares of company stock valued at $1,708,183. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Kura Oncology by 69.7% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after acquiring an additional 233,633 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in Kura Oncology in the 2nd quarter worth about $2,851,000. Tidal Investments LLC acquired a new position in Kura Oncology in the 2nd quarter worth about $1,029,000. Finally, Bank of America Corp DE acquired a new position in Kura Oncology in the 2nd quarter worth about $12,735,000.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.